Pyopneumothorax during bevacizumab-containing chemotherapy in a patient with metastatic breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pyopneumothorax during bevacizumab-containing chemotherapy in a patient with metastatic breast cancer

Published:2015-05-01 Issue:1 Volume:5 Page:40-44
ISSN:2192-3183
Container-title:International Cancer Conference Journal
language:en
Short-container-title:Int Canc Conf J

Author:

Goda Noriko,Kawabuchi Yoshiharu,Watari Masanobu,Kumada Takashi,Kondo Tomohiro,Inoue Satoshi,Yamaguchi Takuro,Kuroo Yuta,Nakamitsu Atsushi

Publisher

Springer Science and Business Media LLC

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

http://link.springer.com/content/pdf/10.1007/s13691-015-0222-x.pdf

Reference15 articles.

1. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676

2. Miles DW, Chan A, Dirix LY et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239–3247

3. Robert NJ, Diéras V, Glaspy J et al (2011) RIBBON-1: randomized, double-blinded, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252–1260

4. Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10:559–568

5. Nalluri SR, Chu D, Keresztes R et al (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:2277–2285

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bevacizumab;Reactions Weekly;2016-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3